Our success in delivering effective doses of siHER2d75 to treat intrinsically resistant HCC1954 tumors [19] prompted us to test it in a model of HER2-positive cancer having acquired resistance to trastuzumab (BT474-TR) and lapatinib (BT474-LR). The gene discussed is ERBB2; the disease is cancer.